Shockwave Medical Inc (NASDAQ:SWAV) shares reached a new 52-week high on Tuesday . The company traded as high as $61.30 and last traded at $61.82, with a volume of 10077 shares changing hands. The stock had previously closed at $57.39.

A number of research analysts have recently weighed in on SWAV shares. Bank of America started coverage on Shockwave Medical in a report on Monday, April 1st. They issued a “neutral” rating and a $37.00 target price on the stock. Morgan Stanley started coverage on Shockwave Medical in a report on Monday, April 1st. They issued an “equal weight” rating and a $32.00 target price on the stock. Finally, Wells Fargo & Co started coverage on Shockwave Medical in a report on Monday, April 1st. They issued a “market perform” rating and a $33.00 target price on the stock.

Shockwave Medical (NASDAQ:SWAV) last posted its earnings results on Wednesday, May 8th. The company reported ($1.37) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.52) by ($0.85). The firm had revenue of $7.27 million during the quarter. Equities research analysts predict that Shockwave Medical Inc will post -2.74 earnings per share for the current fiscal year.

In related news, insider James E. Flynn bought 30,000 shares of the company’s stock in a transaction dated Monday, March 11th. The shares were bought at an average price of $17.00 per share, for a total transaction of $510,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Hedge funds have recently bought and sold shares of the company. Pier Capital LLC bought a new stake in Shockwave Medical during the first quarter worth $335,000. Dean Capital Investments Management LLC bought a new stake in Shockwave Medical during the first quarter worth $658,000. Capital Investment Advisory Services LLC bought a new stake in Shockwave Medical during the first quarter worth $105,000. Wellington Management Group LLP bought a new stake in Shockwave Medical during the first quarter worth $2,486,000. Finally, Citigroup Inc. bought a new stake in Shockwave Medical during the first quarter worth $133,000. Institutional investors own 1.40% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Shockwave Medical (SWAV) Sets New 52-Week High at $61.30” was first reported by Daily Political and is owned by of Daily Political. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at https://www.dailypolitical.com/2019/05/16/shockwave-medical-swav-sets-new-52-week-high-at-61-30.html.

About Shockwave Medical (NASDAQ:SWAV)

ShockWave Medical, Inc, a medical device company, develops and commercializes intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters or treating below-the-knee peripheral artery disease.

See Also: Understanding the different types of bonds

Receive News & Ratings for Shockwave Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shockwave Medical and related companies with MarketBeat.com's FREE daily email newsletter.